IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Ancora Advisors LLC

Ancora Advisors LLC cut its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 835 shares of the company’s stock after selling 226 shares during the period. Ancora Advisors LLC’s holdings in IDEXX Laboratories were worth $345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Aptus Capital Advisors LLC grew its holdings in shares of IDEXX Laboratories by 1,483.8% during the fourth quarter. Aptus Capital Advisors LLC now owns 9,962 shares of the company’s stock worth $4,119,000 after buying an additional 9,333 shares in the last quarter. Wahed Invest LLC boosted its position in IDEXX Laboratories by 2.1% during the fourth quarter. Wahed Invest LLC now owns 2,041 shares of the company’s stock worth $844,000 after acquiring an additional 41 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its stake in IDEXX Laboratories by 7.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,667 shares of the company’s stock valued at $1,929,000 after acquiring an additional 321 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after acquiring an additional 81 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in IDEXX Laboratories by 88.9% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 162,310 shares of the company’s stock worth $67,105,000 after purchasing an additional 76,383 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Down 0.3 %

Shares of NASDAQ IDXX opened at $473.71 on Wednesday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $420.26 and its two-hundred day moving average is $428.49. The firm has a market cap of $38.39 billion, a price-to-earnings ratio of 44.40, a PEG ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. IDEXX Laboratories’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.71 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Morgan Stanley upped their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research report on Monday. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 12th. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Finally, Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $524.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.